Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study

Diagnostic Microbiology and Infectious Disease

Volumn 53, Issue 4, 2005, Pages 273-279

  Turner, Philip J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

MYSTIC; Surveillance data; Website

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; MEROPENEM;

ANTIBIOTIC RESISTANCE; ARTICLE; COMPUTER PROGRAM; DRUG ACTIVITY; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; GEOGRAPHY; HEALTH PROGRAM; HUMAN; INFECTION CONTROL; INFORMATION PROCESSING; KLEBSIELLA PNEUMONIAE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; INFORMATION DISSEMINATION; INTERNET; MICROBIAL SENSITIVITY TESTS; POPULATION SURVEILLANCE; THIENAMYCINS;

EID: 29144506160     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.10.005     Document Type: Article

References (13)

1. L.K. Archibald Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit Clin. Infect. Dis. 24 1997 211 215
2. Clinical and Laboratory Standards Institute (2005) Performance Standards for Antimicrobial Susceptibility Testing, M100-S15.
3. R.N. Jones, and R. Masterton Determining the value of antimicrobial surveillance programs Diagn. Microbiol. Infect. Dis. 41 2001 171 175
4. K.S. Kaye, J.J. Engemann, H.S. Fraimow, and E. Abrutyn Pathogens resistant to antimicrobial agents: epidemiology, molecular mechanisms, and clinical management Infect. Dis. Clin. North Am. 18 2004 467 511 [viii]
5. M. Kollef Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time Drugs 63 2003 2157 2168
6. M.H. Kollef, G. Sherman, S. Ward, and V.J. Fraser Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients Chest 115 1999 462 474
7. R.G. Masterton Surveillance studies: how can they help the management of infection? J. Antimicrob. Chemother. 46 Suppl. T2 2000 53 58
8. R. Masterton, G. Drusano, D.L. Paterson, and G. Park Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges J. Hosp. Infect. 55 Suppl. 1 2003 1 12
9. A.K. Morris, and R.G. Masterton Antibiotic resistance surveillance: action for international studies J. Antimicrob. Chemother. 49 2002 7 10
10. P.R. Rhomberg, R.N. Jones, H.S. Sader, and T.R. Fritsche Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003) Diagn. Microbiol. Infect. Dis. 49 2004 273 281
11. P.J. Turner MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview J. Antimicrob. Chemother. 46 Suppl. T2 2000 9 23
12. P.J. Turner Trends in antimicrobial susceptibilities among bacterial pathogens isolated from patients hospitalised in European medical centres: 6-year report of the MYSTIC Surveillance Study (1997-2002) Diagn. Microbiol. Infect. Dis. 51 2005 281 289
13. P.J. Turner, J.M. Greenhalgh, J.R. Edwards, and J. McKellar The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Programme Int. J. Antimicrob. Agents 13 1999 117 125